drug · gene
CTx-001
Phase 2updated 6mo agoby Complement Therapeutics Ltd🔗 ChEMBL
Phase 2community read0 votes
Gene drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.
indications
indications
AMD
targets
B-cell lymphoma/leukemia 11A
all catalysts(0)
nothing on the calendar yet
Trials studying CTx-001
News(10)
- Cellectis may cut 70% of workforceFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 2h ago
- Beam’s base editing therapy for sickle cell hits goal in pivotal trialThe result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.biopharma_dive · 5d ago
- Beam’s sickle cell therapy results tee up potential Casgevy, Lyfgenia showdownGearing up for a potential FDA filing by the end of the year, Beam Therapeutics revealed results from a phase 1/2 study of its base-edited cell therapy risto-cel, showing the potential sickle cell…fiercebiotech · 5d ago
- Vertex, ahead of FDA decision, calms fears surrounding kidney drugOn a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.biopharma_dive · 12d ago
- Plug-and-play gene therapy: FDA executes on vision that’s been in the works for yearsFormer biologics boss Peter Marks had a vision. With the FDA’s latest draft guidance, it’s coming to fruition. Speaking with BioSpace, current CBER leader Karim Mikhail said the “adapted pathway” i…biospace · 13d ago
- New FDA draft guidance doubles down on expediting approvals of personalized gene therapiesThe FDA has outlined a process for allowing a single application to cover multiple variants of a gene therapy. At the same time, the Centers for Medicare & Medicaid Services has revealed plans to e…biospace · 18d ago
- Most new drugs are still too costly at launch, ICER saysA new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effectiveness guidelines.biopharma_dive · 26d ago
- Biotech startup funding gap widens despite rebound in VC investmentThough funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small startups are being left behind.biopharma_dive · 4mo ago
- Vertex's sickle cell therapy approved for kids; United Therapeutics buys startup🧬 Vertex’s sickle cell gene therapy approved for kids: Casgevy may now be used to treat either sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent β-thalassemia patie…endpoints · 4mo ago
- FDA Approves First Gene Therapy for Young Children with Sickle Cell DiseaseThe U.S. Food and Drug Administration today issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with either sickle cell disease (SCD) with recu…fda_press · 4mo ago
Data sources
last refreshed 28m ago
Found something off?
comments(0)
5-min edit window · permanent after that